PEEL Therapeutics
- Biotech or pharma, therapeutic R&D
Peel Therapeutics engineers evolutionary medicines. Our lead asset is PEEL-224, a differentiated TOP1 inhibitor entering a Phase 1b combination clinical trial for metastatic colorectal cancer (mCRC). The Phase 1 results showed 70% disease control rate in heavily pretreated solid tumors, including a sustained complete response in metastatic pancreatic cancer for over 10 months. Two Investigator Sponsored Trials (ISTs) are now testing PEEL-224 in relapsed sarcoma and pediatric solid tumors.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}